BioMark Diagnostics Inc.
BMKDF
$0.36
$0.000.06%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.24% | 23.28% | 12.21% | 18.16% | -2.80% |
| Total Depreciation and Amortization | -13.17% | -3.16% | 95.98% | 44.28% | 22.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.65% | -76.60% | -72.37% | -73.87% | -32.86% |
| Change in Net Operating Assets | -886.55% | -615.67% | -200.85% | -484.29% | 119.35% |
| Cash from Operations | -1.49% | -0.81% | -62.55% | -16.87% | 2.80% |
| Capital Expenditure | 71.43% | 20.00% | -16,614.81% | -95.35% | 58.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 196.57% | -- | -- | -- | -- |
| Cash from Investing | 196.38% | -11,232.00% | -37,866.67% | -13,867.44% | -27,154.00% |
| Total Debt Issued | -5.55% | -5.55% | 165.39% | 5.88% | 5.88% |
| Total Debt Repaid | -25.77% | -33.43% | 14.26% | 40.93% | 50.08% |
| Issuance of Common Stock | -95.09% | -99.38% | 184.47% | 81.25% | 72.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -108.30% | -111.39% | 392.77% | 166.50% | 179.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,027.34% | -183.13% | 237.41% | 539.80% | 50.58% |